目的: 通过分析日本“价格带”汇总的医保支付标准的调整机制,探讨我国同通用名下医保支付标准的形成路径。方法: 检索日本政府历年发布的医保支付标准调整政策及相关文献,梳理总结日本对于医保支付标准调整方式的变迁、现行调整方法及政策效果。同时分析我国的药品医保支付标准制定所处环境和面临问题。结果: 我国情况与日本类似,同样面临着仿制药支付标准过度细分的问题,而日本通过引入“价格带”汇总机制,将同品规下仿制药支付标准集中控制在3个以内,并结合替代率、上市时间对长期上市原研药的支付标准逐年下调,实现了从“按厂牌”到“按区间”再到“按通用名”制定药品支付标准的转变,解决了药品支付标准过度细分的问题。结论: 我国可以借鉴日本对于药品支付标准调整的经验,针对不同药品应结合分类管理思想,差别选择整合策略,总体上以“三阶段、两路径”循序整合药品支付标准,逐步实现“医保药品支付标准按通用名制定”的改革目标。
Abstract
Objective: The paper introduces the adjustment mechanism of the Japanese “price ranges” medical insurance payment standard, and discusses the formation path of the medical insurance payment standard by generic name in China. Methods: Using drug price policies issued by government of Japan and related literature, the paper summarizes the changes, current adjustment methods and policy effects of Japan's adjustment of medical insurance payment standards, and analyzes the environment and problems faced by China's medical insurance payment standard of drugs. Results: China is similar to Japan, facing the problem of excessive subdivision of generic drug medical insurance payment standards. By introducing the "price ranges" aggregation mechanism, Japan has limited the medical insurance payment standards for generic drugs under the same product regulations to 3. Combined with the replacement rate and time to market, the payment standards for long-term marketed original drugs have been lowered year by year, realizing the transformation from "by brand" "by ranges" to "by generic name" and solving the problem of excessive subdivision of drug payment standards. Conclusion: China can learn from Japan's experience in adjusting drug payment standards. For different drugs, we should combine the idea of classified management, choose the integration strategy differently, and generally integrate the drug payment standards in a sequential manner with " three stages, two paths", and gradually achieve the reform goal of " medical insurance payment standard by generic name " .
关键词
价格带 /
仿制药 /
长期上市药品 /
医保支付标准调整
Key words
price ranges /
generic drugs /
long-term marketed drugs /
medical insurance payment standard adjustment
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 国家医疗保障局.《关于做好当前药品价格管理工作的意见》的通知(医保发〔2019〕67号)[EB/OL].(2019-12-10)[2022-10-24].http://www.gov.cn/xinwen/2019-12/10/content_5459926.htm.
[2] 荣雪菁,孙强.我国相关省份原研药及仿制药价格比较[J].中国卫生经济,2018,37(11):33-36.
[3] 首相官邸.これまでのヒアリングで出された主な意見[EB/OL].(2015-06-05)[2022-10-21].https://www.kantei.go.jp/jp/singi/gskaigi/working/dai6/siryou4.pdf.
[4] 厚生労働省.保険医療機関及び保険医療養担当規則[Z].1957-04-30.
[5] 厚生労働省.保険薬局及び保険薬剤師療養担当規則[Z].1957-04-30.
[6] 常峰,崔鹏磊,夏强,等.日本医保药品支付价格调整机制对我国的启示[J].中国医药工业杂志,2015,46(08):915-920.
[7] 中央社会保険医療協議会.後発医薬品の価格等について(その2)[EB/OL].(2011-12-02)[2022-10-13].https://www.mhlw.go.jp/stf/shingi/2r9852000001ww0z-att/2r9852000001ww4t.pdf.
[8] 厚生労働省.後発医薬品の価格と価格帯について[EB/OL].(2013-11-13)[2022-10-20].https://www.mhlw.go.jp/file/05-Shingikai-12404000-Hokenkyoku-Iryouka/0000029614.pdf.
[9] 日本ジェネリック製薬協会.後発医薬品の採用及び使用の課題に関する調査[EB/OL].(2020-12-23)[2022-10-21].https://www.jga.gr.jp/assets/pdf/archives/report_overview20170519.pdf.
[10] 河口洋行,吉田俊之.我が国における後発医薬品普及に関する政策展開と今後の課題[J]. 成城大学経済研究=Seijo University economic papers,2017(215):127-156.
[11] 厚生労働省.薬価算定の基準について(保発0212第7号)[EB/OL].(2014-02-12)[2022-10-20].https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000039400.pdf.
[12] 厚生労働省.薬価算定の基準について(保発0207第1号)[EB/OL].(2018-02-07)[2022-10-20].https://www.mhlw.go.jp/file/06-Seisakujouhou-12400000-Hokenkyoku/0000193793.pdf.
[13] 王亮,岳晓萌,李钰翔,等.中日医保药品目录管理差异与思考:日本医保目录动态调整机制之启示[J].中国卫生经济,2020,39(05):91-96.
[14] 立石佳代. 後発医薬品使用促進の現状と課題[J].日本大学大学院総合社会情報研究科紀要,2007,8:367-378.
[15] 厚生労働省.令和4年度薬価制度改革について[EB/OL].(2022-03-04)[2022-10-13].https://www.mhlw.go.jp/content/12400000/000942948.pdf.
[16] 岸本堅太郎.経済産業省における創薬イノベーションの取り組みについて[J].ファルマシア,2019,55(1):42-46.
[17] 厚生労働省.令和4年度薬価基準改定の概要[EB/OL].(2022-03-04)[2022-10-13].https://www.mhlw.go.jp/content/12404000/000942947.pdf.
[18] 汤涵,苗采烈,林凡钰,等.中国医药工业发展现状浅析与未来挑战[J].中国医药工业杂志,2021,52(11):1534-1544.
[19] 中国药学会.同一药品已获批准文号企业数在20家以上的过度重复品种目录(第六批)[EB/OL].(2020-08-31)[2022-11-20].https://cpa.org.cn/cpadmn/attached/file/20200904/1599204540285268.pdf.
[20] 刘昀. 试论如何开展医疗保险药品支付标准试点工作[J].质量与市场,2022(10):193-195.
[21] 苏华,郭瑞臣.仿制药一致性评价的背景、实施及结局[J].中国医院药学杂志,2022,42(14):1502-1505.
[22] 李伟,周琳,丁锦希,等.药品质量“一致性评价”对我国医保支付标准影响研究[J].价格理论与实践,2016(08):70-73.
[23] 王皎皎,王昊,杨宏昕.“4+7”带量采购对内蒙古自治区人民医院口服抗肿瘤药原研药和仿制药使用情况影响[J].现代药物与临床,2022,37(08):1872-1878.
[24] 荣雪菁,孙强.我国相关省份原研药及仿制药价格比较[J].中国卫生经济,2018,37(11):33-36.
[25] 丁锦希,潘越,李伟,等.谈判药品医保支付标准调整机制研究——基于一致性评价政策视角[J].中国医疗保险,2018(04):27-32.
基金
国家医疗保障局医药价格和招标采购指导中心课题“药品国内外价格的对比分析”（7422200094）
